-$0.42 Earnings Per Share Expected for Microbot Medical Inc. (NASDAQ:MBOT) This Quarter

Analysts expect Microbot Medical Inc. (NASDAQ:MBOTGet Rating) to announce earnings per share of ($0.42) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Microbot Medical’s earnings. Microbot Medical posted earnings per share of ($0.34) in the same quarter last year, which would suggest a negative year-over-year growth rate of 23.5%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Microbot Medical will report full-year earnings of ($1.62) per share for the current year. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Microbot Medical.

Separately, Zacks Investment Research upgraded Microbot Medical from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th.

Shares of NASDAQ MBOT opened at $4.90 on Thursday. Microbot Medical has a fifty-two week low of $4.31 and a fifty-two week high of $9.60. The firm has a market capitalization of $34.83 million, a P/E ratio of -3.45 and a beta of 3.98. The company’s 50 day simple moving average is $5.74 and its 200 day simple moving average is $5.99.

Several hedge funds have recently made changes to their positions in MBOT. AlphaCentric Advisors LLC bought a new position in shares of Microbot Medical during the 4th quarter valued at about $750,000. Dimensional Fund Advisors LP raised its holdings in Microbot Medical by 78.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 95,064 shares of the biotechnology company’s stock worth $668,000 after buying an additional 41,686 shares during the period. BlackRock Inc. lifted its stake in Microbot Medical by 11.7% in the third quarter. BlackRock Inc. now owns 155,013 shares of the biotechnology company’s stock valued at $1,090,000 after buying an additional 16,205 shares in the last quarter. Morgan Stanley lifted its position in Microbot Medical by 454.7% in the 3rd quarter. Morgan Stanley now owns 19,438 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 15,934 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Microbot Medical during the 4th quarter worth about $95,000. 11.45% of the stock is owned by institutional investors.

About Microbot Medical (Get Rating)

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio.

Featured Articles

Get a free copy of the Zacks research report on Microbot Medical (MBOT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.